Overexpression <i>TRIM37</i> promotes myelin repair and inhibits cell apoptosis by upregulating PEX5. by Lai Jiang (2401513)

Subjects:

Downregulation of TRIM37 expression exacerbates pathological damage in the MS model. by Lai Jiang (2401513)

Subjects:

Primer sequences and information. by Lai Jiang (2401513)

Subjects:

Overexpression <i>TRIM37</i> inhibits inflammatory infiltration and alleviates demyelination in EAE model mice. by Lai Jiang (2401513)

Subjects:

Overexpression <i>TRIM37</i> enhances PEX5 protein stability by promoting PEX5 monoubiquitination. by Lai Jiang (2401513)

Subjects:

DATA_Assessment of awareness level english. by Rayan Saleh Al-Mutairi (21395453)

Subjects:

Proteins significantly modulated by <i>L. donovani</i> infection in dTHP-1 cells. by Harsimran Kaur Brar (8698200)

Asymptotic percentage points for statistic for selected values of the parameter <i>θ</i> with values for different significance levels <i>α</i>. by Héctor Francisco Coronel-Brizio (13014872)

Asymptotic percentage points for statistic for selected values of the parameter <i>θ</i> with values for different significance levels <i>α</i>. by Héctor Francisco Coronel-Brizio (13014872)

A-B. Expression of IRF4 and ELANE in the experimental group compared to the normal control group showed significantly reduced expression levels of IRF4 and ELANE in the MDS disease group, highlighting their potential role in the pathogenesis of these genes. by Min-xiao Wang (20868922)

Subjects:

Association of diabetes risk level and comorbidities patients. by Syed Irfan Karim (10701427)

Subjects:

Selection of genes by level of information at the GWAS locus. by Zeinab Mousavi (20521925)

Correlation analysis, Data show only the values of the correlations that were significant (p < 0.05). by Glaucia Vilar-Pereira (686134)

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Subgroup analyses of TG levels in MDD versus HC. by Di-Ru Xu (19803542)

Subjects:

Characteristics of the included primary studies on HIV-related internalized stigma among people living with HIV/AIDS in Africa. by Gebresilassie Tadesse (18069820)

Subjects:

Sensitivity analysis of HIV-related internalized stigma among people living with HIV/AIDS in Africa. by Gebresilassie Tadesse (18069820)

Subjects:

Flow chart shows study selection for a meta-analysis of HIV-related perceived stigma and internalized stigma among people living with HIV/AIDS in Africa. by Gebresilassie Tadesse (18069820)

Subjects: